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Abstract 
Lacticin 3147 is a dual-acting two-peptide bacteriocin which is generally active against Gram-positive bacteria, including 
Listeria monocytogenes and antimicrobial-resistant bacteria such as Closteroides difficile in the colon. L. monocytogenes 
infections can cause life-long effects in the elderly and vulnerable and can cause severe complications in pregnant women. 
C. difficile causes one of the most common healthcare-associated infections and can be fatal in vulnerable groups such as 
the elderly. Although lacticin 3147 is degraded by intestinal proteases and has poor aqueous solubility, encapsulation of the 
bacteriocin could enable its use as an antimicrobial for treating these bacterial infections locally in the gastrointestinal tract. 
Lacticin 3147 displayed activity in aqueous solutions at a range of pH values and in gastric and intestinal fluids. Exposure 
to trypsin and α-chymotrypsin resulted in complete inactivation, implying that lacticin 3147 should be protected from 
these enzymes to achieve successful local delivery to the gastrointestinal tract. The amount of lacticin 3147 dissolved, i.e. 
its solution concentration, in water or buffered solutions at pH 1.6 and 7.4 was low and varied with time but increased and 
was stabilized in gastrointestinal fluids by the phospholipid and bile salt components present. Thus, the feasibility of a solid 
lipid nanoparticle (SLN) delivery system for local administration of lacticin 3147 was investigated. Bacteriocin activity 
was observed after encapsulation and release from a lipid matrix. Moreover, activity was seen after exposure to degrading 
enzymes. Further optimization of SLN delivery systems could enable the successful pharmaceutical development of active 
lacticin 3147 as an alternative to traditional antibiotics.
Keywords Lacticin 3147 · Bacteriocins · Physicochemical properties · Solid lipid nanoparticles · Drug delivery · 
Antimicrobial resistance
Introduction
Antimicrobial resistance (AMR) occurs when microorgan-
isms evolve in ways that render antibiotics ineffective. The 
number of bacteria becoming resistant to antimicrobial 
drugs is rising constantly due to non-prudent use of antibiot-
ics and the lack of new antimicrobials coming to the market 
[1–3]. Consequently, AMR is endangering the effectiveness 
of a range of drugs that have saved millions of lives [2]. It 
has been projected that by 2050 there could be 10 million 
deaths worldwide per annum due to AMR if this crisis is not 
tackled, exceeding the current number of deaths from cancer 
[4]. Because of this, alternatives to traditional antibiotics, 
such as bacteriocins, are being investigated.
Bacteriocins are small, cationic, heat stable, polypep-
tides that are ribosomally produced by bacteria. Bacteri-
ocins inhibit the growth of competing bacterial strains by 
targeting the cell membrane and/or cell wall or by targeting 
vital processes within the cell, including protein, DNA, and 
RNA metabolism [5]. The Biopharmaceutical Classifica-
tion System (BCS) is used to classify small molecule active 
pharmaceutical ingredients (APIs) based on their aqueous 
solubility and permeability [6]. The knowledge of a small 
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molecule API’s BCS class immediately leads to formulation 
strategies and biowaivers that can expedite their develop-
ment into medicines [7]. For bacteriocins, this classification 
system is somewhat limited. Stability (chemical and enzy-
matic), solubility, unfolding, adsorption to surfaces, aggre-
gation, and permeability are important physicochemical and 
biophysical factors that must be taken into consideration to 
enable the development of these peptides into antibiotics 
[8]. In general, a more in-depth classification system than 
the BCS is required to expedite the development of peptide 
biopharmaceuticals.
Lacticin 3147 is a two-peptide (Ltnα and Ltnβ) bacteri-
ocin produced by Lactococcus lactis DPC6577 (Fig. 1). It is 
classified as a lantibiotic due to the presence of lanthionine 
rings in its structure [9]. The two peptides act synergisti-
cally, targeting lipid II, a precursor of peptidoglycan syn-
thesis in Gram-positive bacteria, leading to inhibition of cell 
wall synthesis, pore formation, and eventual cell death [10]. 
Ltnα exhibits low bacteriostatic activity when assayed alone, 
with a reported minimum inhibitory concentration required 
to inhibit the growth of 50% of bacteria  (MIC50) of 200 nM 
against L. lactis HP. When equal concentrations of Ltnα and 
Ltnβ are added, however, the  MIC50 drops to 7 nM indicat-
ing that the presence of both peptides at a 1:1 molar ratio 
allows for optimum activity [11]. Ltnβ alone has also shown 
bactericidal activity against L. lactis subspecies cremoris at 
high concentrations [12].
Lacticin 3147 is non-toxic to eukaryotic cells [13] and active 
at nanomolar concentrations against several clinically relevant 
bacteria, like L. monocytogenes, and antimicrobial-resistant 
bacteria such as C. difficile and methicillin-resistant S. aureus 
(MRSA) [14–16]. Approximately 223,900 C. difficile infections 
and 12,800 resulting deaths were reported in the USA in 2017 
[17]. Treatment failures and recurrences of infection after the 
use of antibiotics are increasingly common, with a 2–38% fail-
ure rate for vancomycin and 8–50% for metronidazole [18]. A 
more virulent strain of C. difficile, PCR ribotype 027/NAP-1, 
which has recently been identified, is increasing the need for 
alternative therapies [19]. Around 323,700 clinical cases of 
MRSA were recorded in the USA in 2017 resulting in 10,600 
deaths [17]. These figures highlight the urgent need for new 
treatment options for both C. difficile and MRSA infections. 
Although less threatening than C. difficile and MRSA, L. mono-
cytogenes can be especially dangerous for pregnant women, 
leading to severe complications in pregnancy. It can result in 
lifelong health issues or death in the very young and can be 
fatal in elderly and immunocompromised people [20]. Oral 
administration of lacticin 3147 would allow for the treatment 
of C. difficile and L. monocytogenes infections, and its topi-
cal administration could be used to treat S. aureus, including 
MRSA, wound infections. However, the use of bacteriocins as 
medicines is limited due to their inherent physicochemical and 
biophysical properties.
Fig. 1  The structure of the 
lacticin 3147 peptides, Ltnα and 
Ltnβ, illustrating the D-amino 
acid, D-alanine, the dehy-
drated amino acid, dehydrobu-
tyrine (Dhb), and Ala-S-Ala, 
lanthionine, and Abu-S-Ala, 
β-methyllanthionine rings. 
The positively and negatively 
charged residues of the peptides 
are also indicated by plus and 
minus symbols
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Ryan et al. reported that lacticin 3147 was degraded 
and inactivated by trypsin and α-chymotrypsin, digestive 
enzymes found in the small intestines, but that its activ-
ity was unaffected by pepsin [9]. Gardiner et al., however, 
reported that α-chymotrypsin alone degrades lacticin 3147 
[21]. Lacticin 3147 is heat stable, pH stable, and active at 
a neutral pH [9]. However, quantitative data on the amount 
of lacticin 3147 dissolved, i.e. its solution concentration, is 
rarely reported. In fact, only a handful of quantitative solu-
bility studies on bacteriocins can be found in the literature 
[22–24], with activity studies reported in their stead. Bac-
teriocins display low minimum inhibitory concentrations 
(MICs), and thus, only low solution concentrations of pep-
tide are required to demonstrate activity. That said, in many 
cases, pH effects may reduce aqueous solution concentra-
tions to below the MIC at different physiological locations, 
resulting in a loss in efficacy and could also result in the 
precipitation of peptide aggregates in vivo that could induce 
an undesirable immunogenic response.
Additionally, as many proteins are administered paren-
terally due to low bioavailability from oral administration 
[25], long-acting formulations are often desirable to reduce 
the need for frequent administration. Long-acting formu-
lations can be achieved using inherently slow dissolving 
solid phases of the therapeutic or matrices that control the 
release of the therapeutic via diffusion or degradation of the 
matrix. For example, nisin A was released from solid lipid 
nanoparticles (SLNs) and pediocin AcH was released from 
phosphatidylcholine nanovesicles with sustained release of 
15–20 days and 13 days respectively [26, 27]. To design 
such long-acting medicines, the solubility in both aqueous 
and non-aqueous solvent systems is an important parameter to 
ensure efficient encapsulation and the desirable resulting dis-
solution behaviour. This study investigates the stability, solu-
tion concentration, and activity of lacticin 3147 at a range 
of pH values and in solutions that mimic the gastrointestinal 
tract (Fasted State Simulated Gastric Fluid (FASSGF) and 
Intestinal Fluid (FaSSIF)). We explore the suitability of lipid 
formulations to protect lacticin 3147 against proteases. Lac-
ticin 3147 encapsulated in solid lipid nanoparticles shows 
encouraging in vitro activity compared to free lacticin 3147 
suggesting their potential as an alternative local oral treat-




L. Lactis DPC6577 was supplied by our collaborators in 
Teagasc Food Research Centre, Moorepark, Cork, Ireland. 
M17 broth, tryptic soy broth (TSB), tryptic soy agar (TSA), 
XAD16N beads, β-glycerophosphate, ethanol, acetonitrile 
(ACN, ≥ 99.9%), isopropanol (IPA, ≥ 99.9%), methanol 
(MeOH, ≥ 99.9%), acetone, phosphate-buffered saline 
(PBS), trifluoroacetic acid (TFA, ≥ 99.9%), sodium hydrox-
ide (NaOH), potassium chloride (KCl), sodium phosphate 
monobasic monohydrate, trypsin, α-chymotrypsin, pep-
sin, sodium taurocholate hydrate (NaTc, > 97%), L-α-
phosphatidylcholine (lecithin, ∼99% purity, from bovine 
brain), Tween 80, and hydrochloric acid (HCl, 36.4–38%) 
were all purchased from Sigma-Aldrich Ireland Ltd. 
D-glucose, sodium chloride (NaCl), yeast extract, tryp-
tone, magnesium sulfate heptahydrate (MgSO4.7H2O), 
and manganese(II) sulfate tetrahydrate (MnSO4.4H2O) 
were purchased from Fisher Scientific Ireland Ltd. Sinap-
inic acid was purchased from Bruker. Biorelevant fasted 
state simulated intestinal fluid (FaSSIF) powder was pur-
chased from Biorelevant.com Ltd. Geleol™ mono and 
diglycerides and Transcutol® P were gift samples from 
Gattefossé, France. Kolliphor® RH40 was received as a 
gift from BASF, Germany. Deionized water was obtained 
from the Elga PURELAB system.
The production and purification of lacticin 3147
Lacticin 3147 was produced and purified following a pro-
tocol developed by Rea et al. [14]. Briefly, lacticin 3147 
was purified from clarified TY broth using Amberlite XAD 
16 N resin, C18 Solid Phase Extraction (SPE), and finally, 
lacticin 3147 was separated into its individual peptides, 
Ltnα and Ltnβ, by reversed-phase (RP) HPLC.
MALDI‑TOF mass spectrometry
Lacticin 3147 production was confirmed by matrix-
assisted laser desorption ionization-time of f light 
(MALDI-TOF) mass spectrometry using sinapinic acid 
as the matrix [28]. About 0.7 μl of the matrix solution 
(sinapinic acid, 4 mg/ml in 50% acetone/50% metha-
nol) was added to the target plate and left to evaporate 
(30 s) at ambient conditions. Individual peptides (Ltnα 
or Ltnβ) were resuspended in 70% IPA and mixed at 
a 1:1 volume ratio with a 10-mg/ml stock solution of 
sinapinic acid in 60% ACN with 0.1% TFA. About 0.3 μl 
of this peptide-matrix solution was then added to the 
matrix layer previously applied to the plate and evapo-
rated at ambient conditions. The plate was inserted into a 
MALDI-TOF Ultraflex mass spectrometer (Bruker) and 
analysed using reflectron positive 700–3500 Da mode. 
100 shots were fired at 88% intensity. This method was 
also used for the analyses of samples from the enzyme 
degradation studies.
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Bioactivity of lacticin 3147 versus L. monocytogenes 
ATCC 1916
An overnight culture of L. monocytogenes ATCC1916 was 
grown in TSB media supplemented with 6 g/L yeast at 37 °C. 
Freeze-dried Ltnα and Ltnβ were resuspended individually 
in 70% IPA to make a 1-mg/ml solution and filtered through 
a 0.2-µm filter (polyethersulfone) PES filter. They were then 
diluted in sterile PBS to a final peptide concentration of 50 µg/
ml. Peptide solutions were added in triplicate to a 96-well plate 
with sufficient PBS to give a volume of 50 µl. 150 µl of diluted 
bacterial cell culture (optical density (OD) of 0.1 at 595 nm) 
was then added to the wells. Final peptide concentrations of 
150 nM (0.50 µg/ml Ltnα, 0.43 µg/ml Ltnβ), 300 nM (0.99 µg/
ml Ltnα, 0.85 µg/ml Ltnβ), and 400 nM (1.31 µg/ml Ltnα, 
1.14 µg/ml Ltnβ) were obtained when the wells were filled 
to 200 µl. Blanks were set up in triplicate with media only 
and PBS only. The three control wells were also set up with 
bacterial culture and PBS only. The 96-well plate was incu-
bated in a Biotek ELx808 Ultra microplate reader at 37 °C 
for 24 h. Readings were taken at a wavelength of 590 nm 
every 30 min for 24 h with the plate shaken mildly before 
each reading.
Preparation of buffers and fasted state simulated 
gastric and intestinal fluid without enzymes
Phosphate-buffered saline (1 × , pH 6.5) was prepared by dis-
solving one PBS tablet in 200 ml of DI water on a magnetic stir-
rer. After complete dissolution of the tablet, the pH of the buffer 
was confirmed with a pH meter. Hydrochloric acid–potassium 
chloride (HCl/KCl) buffer was prepared by mixing 50 ml of 
200 mM KCl and 10.6 ml of 200 mM HCl in a 100-ml volumet-
ric flask. The pH was then adjusted to pH 2.2 with 1 M NaOH, 
and the volume was made up to 100 mL with DI water. Fasted 
state simulated gastric fluid (FaSSGF) was prepared according 
to the method created by Vertzoni et al. [29], later amended 
by Bannigan et al. [30]. The final composition of the FaSSGF 
consisted of 80 µM NaTc, 20 µM lecithin, 9.1 mM NaCl, and 
25.1 mM HCl. FaSSIF was prepared according to the instruc-
tions provided by the manufacturer (Biorelevant, London, 
England). It had the final composition of 3 mM taurocholate, 
0.75 mM phospholipid, 148 mM sodium, 106 mM chloride, and 
29 mM phosphate. The final solution was equilibrated for 2 h 
to stabilize the micellar particles as per manufacturer’s recom-
mendation. FaSSGF and FaSSIF were stored for 48 h at room 
temperature and used within this time frame.
Lacticin 3147′s activity in phosphate‑buffered 
saline, FaSSIF and FaSSGF
An excess quantity of freeze-dried Ltnα and Ltnβ were 
resuspended individually in PBS buffer/FaSSGF/FaSSIF. 
The samples were then incubated for 0.5 h at 37 ± 0.5 °C 
with stirring at 300 rpm. At the end of the incubation period, 
samples were filtered through a 0.2-µm PES syringe filter 
and employed in the in vitro activity assay. Briefly, 25 µl of 
each of the filtered peptide solutions were added in triplicate 
to the same wells of a 96-well plate. Three control wells 
were set up containing 50  µl of PBS alone. 150  μl of 
L. monocytogenes ATCC 1916 with an OD of 0.1 at 595 nm 
was added to each well. The 96-well plate was then incu-
bated in a Biotek ELx808 Ultra microplate reader at 37 °C 
for 24 h. The readings were taken as previously described.
RP‑HPLC analysis of lacticin 3147
All lacticin 3147 samples were filtered through a 0.2-µm 
PES filter before analysis by RP-HPLC using an Agilent 
1200 Infinity Series HPLC (Agilent Technologies, USA). 
The HPLC separations were carried out on an Aeris 3.6 µm 
Peptide 100 Å 250 × 4.6 mm, liquid chromatography column 
with a flow rate of 0.8 ml/min, and with 0.1% trifluoroacetic 
acid (TFA) in water as aqueous phase-A and 0.1% TFA in 
acetonitrile (ACN) as organic phase-B. The total run time 
was 51 min. The mobile phase started with 30:70 A:B for 
3 min and change linearly to 35:65 A:B over 30 min. The 
organic phase was then adjusted to 100% within 1 min and 
continued to flow for 5 min. After this, the mobile phase 
returned to the initial ratio to stabilize the chromatographic 
system. The detector was set at 214 nm. The peak area 
(mAU) was plotted against the concentration (1.56–500 µg/
ml) to make a calibration curve. The coefficients of deter-
mination (R2 values) were 0.9963 and 0.9983 for Ltnα and 
Ltnβ respectively. This method was subsequently used for 
quantitative analysis of Ltnα and Ltnβ.
Enzyme degradation of lacticin 3147
Trypsin and α-chymotrypsin stock solutions (50 mg/ml) 
were resuspended in water. Pepsin (50 mg/ml) was resus-
pended in 0.02 M HCL. About 1 mg/ml individual solutions 
of Ltnα and Ltnβ in 70% IPA were filtered and diluted (1 
in 20) in sterile PBS to give a final peptide concentration 
of 50 µg/ml. After this, 5.3 µl Ltnα and 4.6 µl Ltnβ were 
added to the same well of a 96-well plate. An equal vol-
ume of enzyme was added to each well (9.9 µl), giving the 
molar ratios as shown in Table 1. The pH of the lacticin 
3147-pepsin solution was 2.29. Control wells consisting of 
Ltnα and Ltnβ together, Ltnα alone, and Ltnβ alone with 
no enzyme were included. The 96-well plate was incubated 
for 3 h at 37 °C to allow the enzyme to act. After incuba-
tion, the wells were filled to 50 μl with PBS and 150 μl 
of diluted bacterial cell culture (L. monocytogenes at an 
OD of 0.1) was added to each well. The final peptide con-
centration of 400 nM (1.31 µg/ml Ltnα, 1.14 µg/ml Ltnβ) 
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was obtained when the wells were filled to 200 µl. Blanks 
were set up in triplicate with media only and PBS only. The 
three control wells were also set up with bacterial culture 
and each enzyme only. The 96-well plate was incubated as 
previously described. The effect of the proteases pepsin, 
α-chymotrypsin, and trypsin on the lacticin 3147 peptides 
was determined by MALDI-TOF mass spectrometry. A 
solution containing 25 mg/ml pepsin, 13.38 µg/ml Ltnα, 
and 11.86 µg/ml Ltnβ was made up and left to incubate for 
3 h (pH 2.29, n = 3). Blanks of Ltnα and Ltnβ alone and 
pepsin alone were included as control samples. After 3 h, 
1 µl was removed from each sample and it was analysed 
by MALDI-TOF mass spectrometry. This was repeated for 
trypsin and α-chymotrypsin (Scheme 1).
Pepsin’s effect on lacticin 3147 was also investigated 
by RP-HPLC. A solution containing 60  mg/ml pepsin 
and 0.0625 mg/ml Ltnα and Ltnβ was made up and was 
incubated at 37 °C for 3 h. After incubation, aliquots were 
taken, filtered, and analysed by RP-HPLC to determine if 
pepsin degrades Ltnα or Ltnβ to any extent.
The effect of pH and gastrointestinal simulated 
fluids on the solution concentration of lacticin 3147
Solutions of the individual lacticin 3147 peptides (500 µg/
ml) were made up in PBS (pH 7.4), HCl/KCl buffer (pH 
2.2), FaSSGF (pH 1.6), FaSSGF without lecithin, FaSSGF 
without NaTc, and FaSSIF (pH 6.5). The solutions were 
stirred at 300 rpm at 37 °C for 0.5 h, then placed in a shak-
ing incubator at 60 rpm and 37 °C. At 0.5 h, 5 h, and 24 h, 
100 µl aliquots of each sample were taken and analysed by 
RP-HPLC. Samples were only taken at 0.5 h and 24 h for 
lacticin 3147 in FaSSGF without lecithin and FaSSGF with-
out NaTc.
Micelle characterization
Solutions of the individual lacticin 3147 peptides (500 µg/
ml) were prepared in FaSSIF, stirred at 300 rpm at 37 °C for 
0.5 h. At 0.5 h, a 1-ml aliquot was taken and filtered through 
a 0.2-µm PES filter. It was analysed for micelle formation 
through dynamic light scattering (DLS) using the Malvern 
Nanozetasizer and a disposable plastic cuvette. The material 
selected was lipid (refractive index 1.5), and the dispersant 
Table 1  The molar ratio of Ltnα/Ltnβ to the digestive enzymes dur-









Scheme 1  Method used to determine the effect of trypsin, α-chymotrypsin and pepsin on lacticin 3147′s activity
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was water (refractive index 1.33). The zeta potential was 
also determined using the same instrument and a disposable 
folded capillary cell.
Encapsulation of lacticin 3147 into solid lipid 
nanoparticles
Preparation of the lacticin 3147 loaded SLNs
SLNs were prepared using the microemulsion template 
technique reported in the literature [31]. About 3–6 mg of 
the individual lacticin 3147 peptides were solubilized in a 
mixture of lipid phase (0.055 g Geleol™- 10% Lecithin) 
maintained at a temperature above its melting point (65 °C) 
with a surfactant-cosurfactant phase (0.25 g Kolliphore® 
RH 40:Transcutol® P, 2:1) and DI water (0.7 ml). This 
formed a warm preconcentrate microemulsion which was 
sonicated for 3 min and then diluted in 5 ml cold water (2–8 °C) 
under stirring at 1000–1200 rpm for 5–7 min to form the 
SLNs dispersion (approximately 6 ml). The SLN solution 
was then filtered to remove any precipitated lacticin 3147. 
Similarly, blank SLNs were also prepared without adding 
lacticin 3147.
Particle size distribution and zeta potential analysis 
of lacticin 3147 loaded SLNs
The particle size and poly diversity index (PDI) of the SLNs 
were measured by photon correlation spectroscopy, using a 
Nanozetasizer (Malvern Instruments Ltd., Worcestershire, 
UK). Samples were diluted 50 times using DI water to 
guarantee that the dispersion was within the instrument’s 
‘dynamic light scattering intensity’ sensitivity range of light. 
The zeta potential of the concentrated solutions was also 
determined using the Nanozetasizer. Measurements were 
carried out in triplicate at 25 °C. The refractive indexes 
selected were 1.5 for the dispersed phase (lipid) and 1.33 
for the dispersant (water).
Determination of total peptide content (TP), free peptide 
content (FP), and encapsulation efficiency (EE%) of lacticin 
3147 loaded SLNs
To determine the total peptide content, lacticin 3147 loaded 
SLN dispersions were diluted with methanol, vortexed, and 
sonicated for 5 min. The samples were filtered using a 0.2-
µm PES syringe filter and analysed by RP-HPLC as dis-
cussed in ‘RP-HPLC analysis of lacticin 3147′. To establish 
the free peptide content of the SLN dispersions, they must 
be destabilized. This was done by adding 200 mg of NaCl 
to 0.5 ml of the dispersions followed by vortexing, then cen-
trifugation for 10 min at 10,000 rpm. This separated the lipid 
(α-SLN and β-SLN) and aqueous phases. The destabilized 
SLN dispersion containing tube was carefully removed from 
the centrifuge and placed in the fridge for 10 min to allow 
the lipid layer to harden. Using a needle, the clear superna-
tant aqueous layer was removed, diluted with IPA, and cen-
trifuged again. It was then filtered using a 0.2-µm PES 
filter and analysed by RP-HPLC to detect the free peptide 
content. The concentration of encapsulated Ltnα and Ltnβ 
was determined by subtracting the free peptide content from 
total peptide content. The encapsulated efficiency of Ltnα 
and Ltnβ was calculated using the following calculation:
Activity of lacticin 3147 SLNs vs free peptide
The activity of the lacticin 3147 SLNs was evaluated using 
the well diffusion assay method [32], on TSA supplemented 
with 6 g/L yeast. The inhibition zones were reported in mil-
limetre (mm) using electronic Vernier callipers. Briefly, 
TSA plates were inoculated with 200 µl L. monocytogenes 
ATCC1916 (OD of 0.1 at 595 nm) under aseptic conditions. 
Wells were bored in the agar after it hardened using a sterile 
6-mm cork borer. α-SLN and β-SLN were filtered using a 
0.2-µm PES filter (SLNs can pass through), and 12.5 µL 
of each was added to the same well. The blank SLNs were 
used as negative controls (25 µL). Ltnα (12.5 µL) and Ltnβ 
(12.5 µL) solutions were used as positive controls. Free 
Ltnα and Ltnβ solutions with the same concentration as the 
TP content of the lacticin 3147 SLNs were suspended in 
water, vortexed, stirred for 5 min at 1100 rpm, and filtered 
to remove any undissolved lacticin 3147. The free peptides 
were filtered again using a 0.2-µm PES filter before addition 
to the wells to ensure sterility. All tests were performed in 
triplicate.
Activity of lacticin 3147 SLNs after incubation 
with α‑chymotrypsin vs free peptide
α-SLN and β-SLN were filtered using a 0.2-µm PES filter, 
and 25 µl of each were added to the same well of a 96-well 
plate. About 50 µl of a 50 mg/ml solution of α-chymotrypsin 
was added to these wells. A blank was set up with 50-µl 
water instead of α-chymotrypsin. This was repeated for free 
peptide solutions prepared as outlined above. The 96-well 
plate was incubated for 3 h at 37 °C. The 96-well plate was 
then removed from the incubator, and 25 µl of each solution 
was added in triplicate to 6-mm wells on TSA (6 g/L yeast) 
plates inoculated with 200 µl L. monocytogenes ATCC1916. 
The plates were incubated at 37 °C for 24 h, after which the 
inhibition zones were measured using an electronic Vernier 
callipers.
Encapsulation efficiency(%) =
total peptide − free peptide
total peptide
× 100




Successful production and purification of lacticin 3147 
from L. lactis DPC6577 were confirmed by MALDI-
TOF mass spectrometry with masses of 3305.341 Da and 
2847.443 Da recorded for Ltnα and Ltnβ respectively 
(Fig. 2). These masses correspond with those previously 
reported in the literature [28]. Lacticin 3147′s activity 
against various strains including L. monocytogenes and C. 
difficile has been previously reported in the literature [11, 
14–16, 33, 34]; however, for the purpose of this study, L. 
monocytogenes was used to establish the impact of solu-
tion composition, pH, and process parameters on its activ-
ity. Our studies found that lacticin 3147 fully inhibited L. 
monocytogenes ATCC1916 at a concentration as low as 
0.99 µg/ml Ltnα and 0.85 µg/ml Ltnβ (300 nM) (Fig. 3a) 
via growth curve assays. Lacticin 3147 was also active 
against L. monocytogenes ATCC 1916 when filtered (to 
remove any undissolved lacticin 3147) after addition 
in excess to PBS (pH 7.4), FaSSGF (pH 1.6), and FaS-
SIF (pH 6.5) (Fig. 3b). This implies more than 0.99 and 
0.85 µg/ml, of Ltnα and Ltnβ respectively dissolved in 
each of these solutions. Ryan et al. reported that lacticin 
3147 is active against L. lactis subsp. cremoris HP at a 
neutral pH [9]. Quantitative solution concentration data is 
important as dissolved lacticin 3147 is required for activ-
ity and for systemic distribution (if desired) in vivo. Lac-
ticin 3147 precipitates/aggregates could also provoke an 
unwanted immune response in patients. The components 
of the media used during in vitro activity assays may be 
necessary for solubilization of the peptide masking solu-
bility challenges that will occur in vivo. The amount of 
lacticin 3147 dissolved in, for example, an aqueous-based 
buffer such as PBS, or simulated bodily fluids such as 
gastrointestinal media, and the stability of these solutions 
in terms of precipitation from solution, has not previously 
been reported.
Enzymatic degradation of lacticin 3147
A study on the effect of the proteases α-chymotrypsin, 
trypsin, and pepsin on the activity of lacticin 3147 was car-
ried out (Fig. 4).
After 3-h incubation with pepsin, lacticin 3147 remains 
active and no increase in bacterial growth compared to lac-
ticin 3147 alone can be seen (Fig. 4). This confirmed that 
pepsin does not degrade either lacticin 3147 peptide as pre-
viously determined by Ryan et al. and Gardiner et al. [9, 
21]. When Ltnα and Ltnβ were incubated with trypsin and 
α-chymotrypsin, a growth curve similar to that of the bacterial 
control can be observed implying that both α-chymotrypsin 
and trypsin degrade at least one of the lacticin 3147 peptides.
Subsequently, MALDI-TOF mass spectrometry on the 
peptides-enzyme solutions after 3 h of incubation was per-
formed (Fig. 5). In the α-chymotrypsin-lacticin 3147 and 
trypsin-lacticin 3147 samples, no masses corresponding to 
intact Ltnα or Ltnβ can be observed (Fig. 5b and c), confirm-
ing that the absence of activity for these solutions in Fig. 4 
is due to the degradation of both lacticin 3147 peptides by 
α-chymotrypsin and trypsin. Masses corresponding to Ltnα 
and Ltnβ can be seen in the pepsin-lacticin 3147 spectrum, 
verifying that neither lacticin 3147 peptide was degraded 
by pepsin.
As MALDI-TOF analysis can only tell us if the peptide 
is present in the sample or not and does not give the con-
centration of Ltnα and Ltnβ in solution after exposure to 
pepsin, RP-HPLC analysis was carried out on the peptide-
pepsin solutions (Fig. 6). It is important to note that the 
ratio of peptide (62.5 µg/ml Ltnα/Ltnβ) to pepsin (60 mg/
ml pepsin) used here is not the same as that used for the 
activity test or the MALDI-TOF analysis. A higher concen-
tration of Ltnα/Ltnβ was required to allow for the detection 
of the lacticin 3147 peptides by RP-HPLC to quantify any 
degradation if it is occurring. This was not repeated for 
α-chymotrypsin or trypsin as the lacticin 3147 peptides 
were shown to be fully degraded by these enzymes via 
MALDI-TOF mass spectrometry analysis (Fig. 5b and c).
Fig. 2  MALDI-TOF mass spec-
tra of lacticin 3147
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The concentrations of Ltnα and Ltnβ with and without 
pepsin are not significantly different (Fig. 6). This shows 
that neither peptide is degraded by pepsin to any detect-
able extent despite the presence of adjacent hydrophobic 
residues, which are targeted by pepsin, in Ltnα (Y11 and 
W12). The location of these target amino acids, in Ltnα’s 
lanthionine B ring, may shield them from the active site 
of pepsin. This is likely as rings A, C, and D were found 
to protect Ltnα from enzyme degradation by Suda et al. 
though ring B was not tested [35].
The effect of pH and biorelevant media 
on the solution concentration of lacticin 3147
Lacticin 3147 is active at very low concentrations. To quan-
tify solution concentrations and monitor solution behaviour, 
a RP-HPLC method was developed. The lowest concentra-
tion detected, i.e. the limit of detection (LOD) of this method, 
was 1.56 µg/ml. It is important to note that the concentration 
required for activity, 0.99 µg/ml Ltnα and 0.85 µg/ml Ltnβ, is 
below the HPLC LOD. The consequence of this is that lacticin 
Fig. 3  The bioactivity of 
lacticin 3147 against L. monocy-
togenes ATCC 1916 when a) 
dissolved in 70% IPA, filtered, 
and then diluted in PBS and b) 
resuspended in excess in PBS, 
FaSSGF, and FaSSIF and then 
filtered
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3147 may not be detectable in solution by HPLC, but there 
may still be enough dissolved to show activity.
Ltnα and Ltnβ’s solution concentration at different pH 
and in biorelevant media was measured. The results of this 
study can be seen in Fig. 7.
A low and variable concentration of dissolved Ltnα and 
Ltnβ can just be detected in solution in PBS buffer and HCl/
KCl buffer. No 24-h time point was taken for Ltnβ in either 
of the buffer solutions due to the absence of a peak on the 
HPLC chromatogram at the 5-h time point, indicating that 
there was no detectable peptide in solution. It is not surpris-
ing that Ltnβ has a lower aqueous solution concentration 
than Ltnα as it is the more hydrophobic peptide, requiring a 
higher % ACN to elute it from the RP-HPLC column during 
purification. Concentrations of 1.7 ± 2.6 µg/ml (Ltnα) and 
2.8 ± 3.9 µg/ml (Ltnβ) were detected in solution in PBS at 
0.5 h, almost double and triple the reported MIC required for 
Ltnα and Ltnβ respectively, although large standard devia-
tions indicate the instability of the solution. This implies that 
for an intravenous aqueous injection of more than double 
the reported MIC of lacticin 3147, solubilizers would be 
needed to stabilize the solution and prevent precipitation of 
the peptide in vivo. It also implies that PBS may not be a 
suitable storage buffer for lacticin 3147.
Ltnα and Ltnβ have isoelectric points (pIs) of 5.32 and 
8.65 respectively [36]. Thus, it was expected that Ltnα and 
Ltnβ’s solution concentration would increase in a pH 2.2 
(KCl/HCl) solution compared to a pH 7.4 (PBS) solution as 
both peptides would be further away from their isoelectric 
point (with a larger positive surface charge) at pH 2.2. The 
highest concentration of dissolved Ltnα detected at pH 2.2 
(11.6 ± 18.1 µg/ml at 24 h) was not significantly different 
from the highest concentration of dissolved Ltnα observed 
in PBS (12.1 ± 11.5 µg/ml at 5 h). The solution concentra-
tion of Ltnβ in PBS and the KCl/HCl buffers at 0.5 h are also 
not significantly different, 2.8 ± 3.9 µg/ml and 2.8 ± 2.0 µg/
ml respectively.
Ltnα initially dissolved in FaSSGF and FaSSIF 
(71.8 ± 117.3 µg/ml and 53.5 ± 80.8 µg/ml respectively), 
but these solution concentrations were extremely unstable 
and showed large standard deviations. The concentration of 
Ltnβ in FaSSGF and FaSSIF at all time points is higher and 
more stable than that of Ltnα and also significantly higher 
than its concentration in PBS or KCl/HCl buffer. About 
164.3 ± 2.1 µg/ml of Ltnβ was found to dissolve in FaSSGF 
(pH 1.6) initially. and it did not change significantly over 
24 h (Fig. 7). From an approximately 500 µg/ml solution 
of Ltnβ in FaSSIF, almost 185.6 ± 29.6 µg/ml was found 
to be in solution initially and decreased to 58.2 ± 4.0 µg/ml 
at 24 h. These results indicate that the components of the 
simulated gastrointestinal fluids solubilize both lacticin 3147 
peptides, with a larger solubilising and stabilising effect on 
Ltnβ than Ltnα.
The concentration of NaTc in FaSSGF, 80 µM, is below 
the critical micelle concentration (CMC) value for a 4:1 
NaTc:lecithin solution, 250 µM [37]. Thus, encapsulation 
into micelles can be ruled out as the cause for increased 
lacticin 3147 solubility in FaSSGF. However, Ltnα and Ltnβ 
must be interacting with the lecithin and NaTc molecules 
present, resulting in an increase in their solution concentra-
tion, since a higher concentration of Ltnα and Ltnβ in solu-
tion was observed in FaSSGF compared to in the HCl/KCl 
pH 2 buffer. The solution concentration of Ltnα and Ltnβ in 
FaSSGF without lecithin and without NaTc was investigated 
Fig. 4  The effect of 25 mg/ml 
pepsin, α-chymotrypsin, and 
trypsin on lacticin 3147′s activ-
ity against L. monocytogenes 
ATCC 1916
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Fig. 5  MALDI-TOF mass 
spectra of lacticin 3147 incu-
bated for 3 h with a) water, b) 
α-chymotrypsin, c) trypsin, and 
d) pepsin and compared to an 
α-chymotrypsin/trypsin/pepsin 
blank
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to determine the effect of the individual substances on the 
solution concentration of lacticin 3147 (Fig. 8).
From the above figure, it can be deduced that NaTc 
causes an increase in the solution concentration of Ltnα 
and Ltnβ but that lecithin is also required to keep Ltnβ in 
solution.
The concentration of NaTc in FaSSIF, 3 mM, is above the 
CMC value for a 4:1 NaTc:phospholipid solution, 0.25 mM 
[37]. Because of this, it is feasible that the increase in the 
concentration of dissolved Ltnα and Ltnβ in FaSSIF could be 
due to their entrapment into micelles. Ltnβ was more soluble 
and remains dissolved in the FaSSIF solution longer than 
Ltnα (Fig. 7). The entrapment of molecules into micelles 
relies on hydrophobic interactions between the hydrophobic 
tails of the lipids and the molecule. Therefore, the higher 
hydrophobicity of Ltnβ could account for its higher concen-
tration in solution. Ltnβ is also positively charged at pH 6.5. 
This would also allow it to bind to the negatively charged 
head groups of the micelles or individual phospholipid and 
taurochlorate molecules, thus increasing the amount of Ltnβ 
dissolved in solution. Ltnα is negatively charged at pH 6.5 
and therefore, would be repelled from the head groups, and 
only encapsulation into the hydrophobic core of the micelles 
would increase its solution concentration.
To determine the presence of micelles in solution, FaSSIF 
was analysed by dynamic light scattering (DLS) with a zeta 
sizer in the nano range (Fig. 9). A peak was seen at 53 nm 
indicating that NaTc/phospholipid micelles are present in 
the FaSSIF solution. An increase in size of the micelles was 
observed in the FaSSIF solutions containing the lacticin 
3147 peptides. This indicates the inclusion of both Ltnα and 
Ltnβ into the micelle structure, although a larger increase 
in size with Ltnα was observed. This could perhaps be due 
to the repulsion of the negatively charged Ltnα from the 
charged head groups of the phospholipid and taurochlorate 
molecules and predominant encapsulation inside the hydro-
phobic core of the micelles. Zeta potential measurements 
were conducted to probe whether the Ltnα or Ltnβ inter-
act with the ionic head groups of the micelles. The results 
showed an increase of zeta potential of + 3.3 and + 5.5 mV 
Fig. 6  Concentration of the 
individual lacticin 3147 pep-
tides (approximately 62.5 µg/
ml) with and without pepsin 
(60 mg/ml)
Fig. 7  Solution concentrations 
of Ltnα (left n = 3) and Ltnβ 
(right n = 2, FaSSIF n = 3) after 
addition of 500 µg/ml peptide 
in PBS buffer, HCl/KCl buffer, 
FaSSGF, and FaSSIF at 37 °C 
with stirring at 300 rpm for the 
first 0.5 h and subsequent shak-
ing at 60 rpm at 37 °C followed 
by filtration and HPLC analysis
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for FaSSIF containing Ltnα and Ltnβ respectively compared 
to FaSSIF alone after 24 h. This indicated that while Ltnα 
appears to be encapsulated into the core of the micelles, 
increasing their size, the more favourable positive charge 
on Ltnβ may increase binding to the micelle surface or indi-
vidual phospholipid and taurochlorate molecules by electro-
static interactions, leading to a greater concentration of Ltnβ 
in solution overall.
Solid lipid nanoparticles as a formulation strategy 
for the delivery of lacticin 3147
The low and unstable aqueous solubilities of Ltnα and 
Ltnβ in PBS, Ltnα in FaSSGF and FaSSIF, and to a lesser 
degree, Ltnβ in FaSSGF and FaSSIF, mean that formulation 
strategies will be needed for all routes of administration of 
lacticin 3147. In PBS, solution concentrations only reached 
approximately double the required MIC against L. monocy-
togenes ATCC 1916 and these concentrations were unstable 
over time. This would be a cause for concern for parenteral 
administration [8]. At solution pH values below their pI, 
the solubility of neither lacticin 3147 peptide improved. 
Thus, parenteral administration of lacticin 3147 solutions 
will require solubilising and stabilising additives to prevent 
aggregation and potential immunogenic responses in vivo. 
Lacticin 3147 displays hydrophobic characteristics in solu-
tion and an affinity to interact with the lipids and bile salts 
present in gastrointestinal (GI) fluid. This could be advanta-
geous for its development into a topical lipid-based therapy, 
increasing its solubility and its permeability into the dermis 
and epidermis layers of the skin when treating S. aureus 
infections locally.
Fig. 8  Solution concentrations 
(µg/ml) of Ltnα (left) and Ltnβ 
(right) after addition of 500 µg/
ml peptide in FaSSGF (GF), GF 
without lecithin, and GF with-
out NaTc at 37 °C with stirring 
at 300 rpm for the first 0.5 h and 
subsequent shaking at 60 rpm
Fig. 9  Measurement of micelle 
size distribution in FaSSIF in 
the absence or presence of Ltnα 
or Ltnβ at 0.5 h
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For oral administration, it was observed that the endog-
enous components of the GI tract enhanced the solubility of 
both Ltnα and Ltnβ. This is promising as L. monocytogenes 
and C. difficile infections in the colon are potential targets 
for lacticin 3147. Lacticin 3147, however, is susceptible 
to enzyme degradation by trypsin and α-chymotrypsin in 
the lower digestive tract. Thus, to enable the lacticin 3147 
peptides to act in the colon, they would need to be formu-
lated in a way that protects them from this degradation. The 
degradation of lacticin 3147 by digestive enzymes could be 
overcome by nanocarrier based technology thus improving 
oral delivery efficiency. Amongst all nanocarriers, SLNs are 
considered to be superior for protection of actives against 
hostile GI environment by encapsulating actives in a solid 
matrix [38]. The increase in the solution concentration of 
lacticin 3147 caused by the presence of phospholipids and 
bile salts in FaSSGF/FaSSIF also indicates lipid systems as 
a potential suitable formulation strategy for lacticin 3147. 
Additionally, SLNs can be produced on a large scale [26], 
are highly stable, and can improve the bioavailability of a 
drug [39]. They also show excellent biocompatibility, thus 
demonstrating wide acceptability by the human body [38, 
40]. Thus, lacticin 3147 peptides were encapsulated in SLNs 
and their ability to protect Ltnα and Ltnβ from digestive 
enzymes was investigated.
Preliminary studies revealed better solubility of lacticin 
3147 in geleol compared to other lipids (softisan 601 and 
glycerol monostearate) as determined by visual observa-
tion; hence, this was used for further studies. Geleol has the 
melting point between 54 and 64 °C, therefore was melted 
at 65 °C and maintained at this temperature until the final 
dilution step. As lacticin 3147 is heat stable, its exposure 
to such a temperature should not affect its activity [9]. In 
the present work, an SLN preparation was carried out using 
a microemulsion templating technique whose composition 
was derived by plotting pseudoternary phase diagrams (data 
not shown). This technique does not require the use of any 
organic solvents or post-processing steps like probe soni-
cation or homogenization [40]. Lecithin was incorporated 
into the lipid matrix as an additional stabilizer. To further 
reduce the interfacial tension and to impart stabilization 
on the SLNs, a cosurfactant was used together with the 
surfactants [41]. Several trials were conducted by vary-
ing the surfactant type (Kolliphore® H515, Kolliphore® 
RH40, Labrasol and polysorbate 80, and at a 2:1 ratio with 
the co-surfactant Transcutol® P) and the concentration of 
surfactant (0.015–0.05 mg/ml) and lipid (0.005–0.01 mg/
ml). Amongst all, Kolliphore® RH:40-Transcutol P (2:1) at 
0.042 mg/ml and Geleol-10% lecithin at 0.0092 mg/ml gave 
stable solid lipid nanoparticles (Scheme 2).
The particle sizes obtained for Ltnα, Ltnβ, and blank 
SLNs, irrespective of the exact mass of peptide added, were 
85 ± 3 nm (PDI: 0.22 ± 0.01), 81 ± 8 nm (PDI: 0.21 ± 0.01), 
and 82 ± 15 nm (PDI: 0.22) respectively. This demonstrates 
that there was no significant difference in the size of the 
SLNs in any of the batches with or without peptides. Simi-
larly, the encapsulation of the bacteriocin nisin Z into nano 
micelles by Sadiq et al. did not cause a significant increase in 
size [42]. The particle sizes obtained here are similar to that 
reported in the literature for local delivery to the colon [43, 
44]. The narrow PDIs of these dispersions indicate homoge-
neous SLNs of uniform size. The encapsulation of Ltnα and 
Ltnβ increased the zeta potential of the SLNs by + 4.6 ± 0.9 
and + 3.6 ± 0.3 respectively. This value was irrespective 
of the mass of each peptide added in the range of peptide 
loadings used, 3–6 mg. The increase of the zeta potential 
indicates that there must be some interaction between the 
peptides and the SLN surface composition.
Scheme 2  Method used to prepare solid lipid nanoparticles of lacticin 3147
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The encapsulation efficiency of Ltnα was 16 ± 6%, 
while the encapsulation efficiency of Ltnβ was 84 ± 8%. 
Ltnβ has previously shown to be the more hydrophobic 
peptide where the presence of micelles in FaSSIF led 
to a greater increase in solubility for Ltnβ than Ltnα. 
Thus, it is not surprising that a higher encapsulation 
efficiency was obtained for Ltnβ into the hydrophobic 
geleol SLNs.
An in vitro well diffusion assay (WDA) was performed 
to evaluate the activity of encapsulated peptide in SLNs 
versus free peptides (Fig. 10). A WDA was chosen instead 
of growth curve assays previously used for the previous 
activity studies as complete killing was seen for both 
solutions when tested by growth curve assays. The WDA 
method allowed for the extent of killing by each to be com-
pared. The free peptides were suspended in water at the 
same concentration as the total peptide content determined 
for the lacticin 3147 SLNs used in the assay. The free pep-
tide suspensions were vortexed briefly, stirred for 5 min 
at 1100 rpm, and then filtered to remove any undissolved 
lacticin 3147. They were filtered again before addition to 
the agar plate to ensure sterility.
The larger zone of inhibition observed with the lacticin 
3147 SLNs, 17.6 ± 0.5 mm, compared to those observed 
with free lacticin 3147, 12.9 ± 0.3 mm, indicates (i) the 
retention of activity of Ltnα and Ltnβ post encapsulation and 
(ii) an increase in antimicrobial activity in water due to the 
encapsulation into SLNs. The amount of free peptide added 
to water in Fig. 10 (left) was the same as the total peptide 
content of the SLNs in Fig. 10 (right). Both the free lacticin 
3147 peptide solutions and the α-SLN and β-SLN suspen-
sions were filtered before addition to the plate to remove 
any undissolved lacticin 3147 and ensuring sterility. Thus, 
the encapsulated peptides account for the larger inhibition 
zone observed, i.e. greater activity is seen in the α-SLN and 
β-SLN plate compared to the aqueous solution of free Ltnα 
and Ltnβ. No zone of inhibition was seen for the blank SLNs 
(Fig. 10 (bottom)), indicating that all killing observed in the 
lacticin 3147 samples were due to lacticin 3147 only and not 
the components of the SLNs.
As previously determined, Ltnα and Ltnβ are fully 
degraded by α-chymotrypsin, leading to the loss of their 
activity. To determine if the encapsulation of the lacticin 
3147 peptides into SLNs can protect them from enzymatic 
Fig. 10  The zones of inhibition 
after the addition of combined 
free Ltnα and Ltnβ solutions 
(left), combined α-SLN and 
β-SLN dispersions (right), and 
blank SLN dispersions (bot-
tom) against L. monocytogenes 
ATCC 1916. All samples were 
filtered before addition to the 
wells (n = 2)
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degradation, both free Ltnα and Ltnβ and α-SLN and β-SLN 
were incubated with α-chymotrypsin and then tested for 
activity (Fig. 11).
Small, yet significant, distinct zones of inhibition were 
present around the lacticin 3147 SLNs after incubation with 
α-chymotrypsin (Fig. 11 (left)), of size 7.4 ± 0.9 mm, com-
pared to barely visible zones with the free peptides incubated 
with the same, 6.0 ± 0.1 mm (Fig. 11 (right)). This indicates 
the ability of the SLNs to protect lacticin 3147 from deg-
radation by this enzyme to some extent. It is important to 
note, however, that α-chymotrypsin is still active during the 
24-h incubation with L. monocytogenes. This means that 
although lacticin 3147 was protected by the SLNs during the 
3-h incubation with α-chymotrypsin, some of the peptides 
are likely to have been degraded when released out of the 
SLNs while in the wells of the agar plate. The zones of inhi-
bition present are caused by the lacticin 3147 that survived 
degradation throughout the 24-h incubation (as the enzyme 
was not deactivated during this incubation period), meaning 
that the protective effect of the SLNs seen here may be less 
than what would be seen after only 3 h of incubation with 
α-chymotrypsin. Further studies are required to determine 
the exact level of protection they provide.
Successful encapsulation and retention of activity of Ltnα 
and Ltnβ indicate the feasibility of SLNs as a delivery sys-
tem of lacticin 3147. The ability of the SLNs to protect the 
lacticin 3147 peptides from degradation by α-chymotrypsin 
indicates their potential for delivering intact lacticin 3147 to 
treat infections in the intestine or colon.
Conclusion
Lacticin 3147 was shown to have low and unstable aqueous 
solution concentrations over a range of pH solutions from 
pH 1.6 to pH 7.4, despite demonstrating activity at such pH 
values. This activity is due to lacticin 3147′s potency and 
low MIC values. A bioactive’s physicochemical properties 
can suggest potential delivery strategies early on that may 
enable its success at later stages of development. Lacticin 
3147′s poor aqueous solubility and susceptibility to proteo-
lytic degradation will necessitate solubilization and encap-
sulation strategies for its success in vivo. The increase in 
the solution concentration of lacticin 3147 peptides caused 
by the presence of phospholipid molecules and NaTc sur-
factant molecules in biorelevant media FASSIF indicated 
that lipid systems could be a potential formulation strategy. 
Ltnα and Ltnβ retained activity when encapsulated into 
solid lipid nanoparticles and demonstrated enhanced activ-
ity compared to free lacticin 3147. Lacticin 3147 SLNs also 
showed activity after incubation with α-chymotrypsin, dis-
playing the potential ability of SLNs’ to protect the lacticin 
3147 peptides from degradation by this enzyme. Further 
optimization of such lipid delivery systems could deliver 
intact lacticin 3147 successfully to the colon to fight bac-
terial infections or indeed could increase the permeability 
of a lacticin 3147 topical treatment for infected wounds, 
enabling its development as an alternative to existing 
antibiotics.
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